Fabricio Alarcon, MD
Internal Medicine · Georgetown, DENPI 1134184278
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,215 of the $29,565 with a category attached, or 78.5%. Novo Nordisk accounts for 80.6% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $18,986 and has fallen 99.0% since, to $188 in 2025. Among internal medicine clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $139.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$24K
- AbbVie$3K
- AstraZeneca$288
- Lilly USA, LLC$279
- Pfizer$213
- Boehringer Ingelheim$201
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$23,21579%
- Travel & lodging$1,8556%
- Food & beverage$4,40815%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $23,815 |
| AbbVie(2 entities) | 14 | $3,485 |
| AstraZeneca | 16 | $288 |
| Lilly USA, LLC | 17 | $279 |
| Pfizer | 14 | $213 |
| Boehringer Ingelheim | 12 | $201 |
| Astellas Pharma US Inc | 7 | $178 |
| Novartis | 7 | $110 |
| Indivior Inc. | 5 | $107 |
| Amgen | 5 | $84 |
| Johnson & Johnson | 4 | $83 |
| Idorsia Pharmaceuticals US Inc | 1 | $73 |
| Abbott | 3 | $62 |
| Gilead | 3 | $57 |
| Alkermes, Inc. | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $55 |
| Eisai Inc. | 3 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $52 |
| Dexcom, Inc. | 2 | $42 |
| Braeburn Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Merck | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Shire North American Group Inc | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,565 in reported general payments places this provider in the 95th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 160 | $190,724 |
| OzempicSemaglutide | 95 | $149,506 |
| EliquisApixaban | 158 | $111,750 |
| JanuviaSitagliptin Phosphate | 73 | $79,962 |
| MyrbetriqMirabegron | 88 | $55,294 |
| XifaxanRifaximin | 12 | $41,623 |
| LinzessLinaclotide | 34 | $32,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $27,329 |
| FarxigaDapagliflozin Propanediol | 34 | $26,628 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $22,767 |
| EntrestoSacubitril/Valsartan | 20 | $22,486 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $20,787 |
| TrulicityDulaglutide | 11 | $19,311 |
| XareltoRivaroxaban | 18 | $19,275 |
| BriviactBrivaracetam | 11 | $16,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $201 | $190,724160 claims |
| Novo NordiskOzempic | $23,815 | $149,50695 claims |
| PfizerEliquis | $213 | $111,750158 claims |
| MerckJanuvia, Janumet | $27 | $100,749104 claims |
| AbbVieLinzess, Creon, Restasis | $3,485 | $56,92458 claims |
| Astellas Pharma US IncMyrbetriq | $178 | $55,29488 claims |
| AstraZenecaFarxiga | $288 | $26,62834 claims |
| NovartisEntresto | $110 | $22,48620 claims |
| Lilly USA, LLCTrulicity | $279 | $19,31111 claims |
| Johnson & JohnsonXarelto | $83 | $19,27518 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $52 | $10,45812 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $7,82113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Georgetown
- Beshara HelouGeorgetown$143K
- Seth IvinsNewark$384K
- Tabassum SalamNewark$62K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
- Fadi DamouniMillsboro$17K
- Rene BadilloBear$16K
- Robert KopeckiWilmington$15K
- Franklin AmpaduWilmington$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.